CU20170093A7 - Conjugados de ácidos grasos y apelina sintética con mayor vida media - Google Patents

Conjugados de ácidos grasos y apelina sintética con mayor vida media

Info

Publication number
CU20170093A7
CU20170093A7 CUP2017000093A CU20170093A CU20170093A7 CU 20170093 A7 CU20170093 A7 CU 20170093A7 CU P2017000093 A CUP2017000093 A CU P2017000093A CU 20170093 A CU20170093 A CU 20170093A CU 20170093 A7 CU20170093 A7 CU 20170093A7
Authority
CU
Cuba
Prior art keywords
conjugates
heart failure
fatty acid
synthetic
appeal
Prior art date
Application number
CUP2017000093A
Other languages
English (en)
Inventor
Aaron Kanter
Aimee Richardson Usera
Frederic Zecri
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20170093A7 publication Critical patent/CU20170093A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

<p>La invención proporciona un conjugado, o una sal farmacéuticamente aceptable del mismo, que comprende un polipéptido sintético de Fórmula I:<br /> <br /> Q-R-P-R-L-C*-H-K-G-P-(Nie)-C*-F (I) o una amida o éster del mismo; y un ácido graso seleccionado de:</p> <p>ESPACIO PARA FÓRMULA</p> <p>en el que dicho ácido graso está unido covalentemente al extremo N-terminal del péptido a través de una de sus funcionalidades de ácido carboxílico, opcionalmente a través de un enlazador de polietilenglicol; y en el que los dos aminoácidos de cisteína marcados con "*" forman un enlace disulfuro entre las funcionalidades tiol de su cadena lateral. Los conjugados son agonistas del receptor APJ. La invención también se refiere a un método para Ia fabricación de los conjugados de Ia invención y sus usos terapéuticos, tales como el tratamiento o Ia prevención de insuficiencia cardíaca aguda descompensada (ICAD), insuficiencia cardíaca crónica, hipertensión pulmonar, fibrilación atrial, síndrome de Brugada, taquicardia ventricular, aterosclerosis, hipertensión, restenosis, enfermedades isquémicas cardiovasculares, cardiomiopatía, fibrosis cardíaca, arritmias, retención de agua, diabetes (incluyendo diabetes gestacional), obesidad, enfermedad arterial periferica, accidentes cerebrovasculares, ataques isquémicos transitorios, lesiones cerebrales traumáticas, esclerosis lateral amiotrófica, quemaduras (incluyendo quemaduras de sol) y preeclampsia. La presente invención proporciona además una combinación da agentes farmacológicamente activos y una composición farmacéutica.</p>
CUP2017000093A 2015-01-23 2016-01-15 Conjugados de ácidos grasos y apelina sintética con mayor vida media CU20170093A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562107040P 2015-01-23 2015-01-23
PCT/IB2016/050206 WO2016116842A1 (en) 2015-01-23 2016-01-15 Synthetic apelin fatty acid conjugates with improved half-life

Publications (1)

Publication Number Publication Date
CU20170093A7 true CU20170093A7 (es) 2017-09-06

Family

ID=55229773

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000093A CU20170093A7 (es) 2015-01-23 2016-01-15 Conjugados de ácidos grasos y apelina sintética con mayor vida media

Country Status (22)

Country Link
US (1) US9931372B2 (es)
EP (1) EP3247405B1 (es)
JP (1) JP2018507187A (es)
KR (1) KR20170103970A (es)
CN (1) CN107406490A (es)
AR (1) AR104479A1 (es)
AU (1) AU2016209968B2 (es)
BR (1) BR112017014194A2 (es)
CA (1) CA2972871A1 (es)
CO (1) CO2017007244A2 (es)
CR (1) CR20170338A (es)
CU (1) CU20170093A7 (es)
EA (1) EA201791668A1 (es)
IL (1) IL253105A0 (es)
MA (1) MA41580A (es)
MX (1) MX2017009534A (es)
PE (1) PE20171328A1 (es)
PH (1) PH12017501112A1 (es)
SG (1) SG11201704758XA (es)
TW (1) TW201632197A (es)
UY (1) UY36523A (es)
WO (1) WO2016116842A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3684414A4 (en) * 2017-09-19 2021-06-09 Immunwork Inc. PHARMACEUTICAL CONSTRUCTIONS WITH IMPROVED BINDING AFFINITY WITH ALBUMIN
WO2019229242A1 (en) 2018-05-31 2019-12-05 Novo Nordisk A/S Derivatives comprising an apelin analogue and uses thereof
TW202304500A (zh) * 2021-04-21 2023-02-01 瑞士商諾華公司 升糖素樣肽化合物

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
DE3347565A1 (de) 1983-12-30 1985-07-11 Thomae Gmbh Dr K Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPS6354321A (ja) 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
DK0512042T3 (da) 1990-01-24 1998-05-11 Douglas I Buckley GLP-1-analoger anvendelige ved diabetesbehandling
AU654331B2 (en) 1991-03-30 1994-11-03 Kissei Pharmaceutical Co. Ltd. Succinic acid compounds
US5155100A (en) 1991-05-01 1992-10-13 Ciba-Geigy Corporation Phosphono/biaryl substituted dipeptide derivatives
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
KR100496720B1 (ko) 1991-06-21 2006-01-27 닥터.칼토매게엠베하 (s)(+)-2-에톡시-4[n-[1-(2-피페리디노페닐)-3-메틸-1-부틸]아미노카보닐메틸]-벤조산을함유하는당뇨병치료제
ATE149483T1 (de) 1991-07-30 1997-03-15 Ajinomoto Kk Kristalle von n-(trans-4- isopropylcyclohexylcarbonyl)-d-phenylalanin und verfahren zu ihrer herstellung
WO1993011782A1 (en) 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
JPH09501655A (ja) * 1993-08-02 1997-02-18 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション 治療化合物−脂肪酸接合体
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
TW313568B (es) 1994-12-20 1997-08-21 Hoffmann La Roche
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DE69838986T2 (de) 1997-12-24 2009-01-08 Takeda Pharmaceutical Co. Ltd. Polypeptide, deren herstellung und verwendung
AU2605099A (en) * 1998-02-25 1999-09-15 Micrologix Biotech, Inc. Indolicidin and cationic peptides conjugated with polymers
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6723752B2 (en) 1999-09-23 2004-04-20 Pharmacia Corporation (R)-chiral halogenated substituted n-benzyl-n-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
AU2001242749A1 (en) 2000-03-23 2001-10-03 Takeda Chemical Industries Ltd. Peptide derivative
HUP0301335A3 (en) 2000-04-12 2006-02-28 Novartis Ag Combination of organic compounds
DK2128246T3 (da) 2001-04-19 2014-05-12 Univ California Fremgangsmåder og sammensætninger til fremstilling af ortogonale tRNA-aminoacyl-tRNA-syntetasepar.
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
TW200407310A (en) 2002-06-07 2004-05-16 Glaxo Group Ltd Compounds
ATE335744T1 (de) 2002-08-07 2006-09-15 Novartis Pharma Gmbh Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen
US7223866B2 (en) 2002-11-18 2007-05-29 Novartis Ag Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases
WO2004078777A2 (en) * 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins
EA200601785A1 (ru) 2004-03-26 2007-02-27 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
BRPI0511621A (pt) 2004-05-28 2008-01-02 Speedel Experimenta Ag compostos orgánicos
US7612088B2 (en) 2004-05-28 2009-11-03 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
TW200608978A (en) 2004-05-28 2006-03-16 Speedel Experimenta Ag Organic compounds
AR049711A1 (es) 2004-07-09 2006-08-30 Speedel Experimenta Ag Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
AR056888A1 (es) 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
EA014232B1 (ru) 2005-12-20 2010-10-29 Бристол-Маерс Сквибб Компани Стабильные белковые препараты
US20090156875A1 (en) 2006-04-04 2009-06-18 Takafumi Tomioka Methane separation method, methane separation apparatus, and methane utilization system
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
AU2007247385B2 (en) 2006-05-10 2011-07-14 Novartis Ag Bicyclic derivatives as CETP inhibitors
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
CA2657258A1 (en) 2006-07-20 2008-01-24 Novartis Ag Amino-piperidine derivatives as cetp inhibitors
US20090264420A1 (en) 2006-08-25 2009-10-22 Gary Michael Ksander Organic compounds
US8043829B2 (en) * 2006-10-25 2011-10-25 Amgen Inc. DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
KR20090091817A (ko) 2006-12-18 2009-08-28 노파르티스 아게 알도스테론 신타제 억제제로서의 이미다졸
US8143278B2 (en) 2006-12-18 2012-03-27 Novartis Ag Organic compounds
US20100041722A1 (en) 2006-12-18 2010-02-18 Qi-Ying Hu Organic compounds
WO2008119744A1 (en) 2007-03-29 2008-10-09 Novartis Ag Heterocyclic spiro-compounds
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
WO2009035543A1 (en) 2007-09-07 2009-03-19 Theravance, Inc. Dual-acting antihypertensive agents
CA2704633C (en) 2007-11-05 2015-10-20 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
PT2229356E (pt) 2007-12-03 2012-01-20 Novartis Ag Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
WO2009134741A1 (en) 2008-04-29 2009-11-05 Theravance, Inc. Dual-acting antihypertensive agents
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
KR20110039348A (ko) * 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
KR101316159B1 (ko) 2008-10-24 2013-10-15 아이알엠 엘엘씨 생합성적으로 생성된 피롤린-카르복시-리신, 및 피롤린-카르복시-리신 및 피롤리신 잔기의 화학적 유도체화를 통한 부위 특이적 단백질 변형
WO2010053545A2 (en) * 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Apj receptor compounds
KR101338555B1 (ko) 2009-05-15 2013-12-09 노파르티스 아게 알도스테론 신타제 억제제로서의 아릴 피리딘
CA2763572C (en) 2009-05-28 2017-10-17 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
MA33364B1 (fr) 2009-05-28 2012-06-01 Novartis Ag Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CN106139158B (zh) * 2010-01-22 2024-06-21 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
CN103179976A (zh) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 呈现g蛋白偶联受体活性的胰高血糖素超家族肽
SI3045183T1 (sl) 2011-03-11 2018-11-30 Genzyme Corporation Pegiliran Apelin in njegove uporabe
CA2860740A1 (en) * 2012-01-09 2013-07-18 Anchor Therapeutics, Inc. Apj receptor compounds
ES2875957T3 (es) 2012-12-20 2021-11-11 Amgen Inc Agonistas del receptor APJ y usos de los mismos
BR112015020587A2 (pt) 2013-03-14 2017-10-10 Regeneron Pharma proteínas de fusão de apelina e suas utilizações
AU2014293387B2 (en) * 2013-07-25 2017-04-20 Novartis Ag Bioconjugates of synthetic apelin polypeptides
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
MX370689B (es) 2014-06-10 2019-12-19 Amgen Inc Polipeptidos apelina.
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20170355734A1 (en) 2014-12-23 2017-12-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Metabolically Stable Apelin Analogs in the Treatment of Disease Mediated by the Apelin Receptor

Also Published As

Publication number Publication date
BR112017014194A2 (pt) 2018-01-09
EP3247405A1 (en) 2017-11-29
US9931372B2 (en) 2018-04-03
JP2018507187A (ja) 2018-03-15
CR20170338A (es) 2017-09-12
PE20171328A1 (es) 2017-09-12
US20160213743A1 (en) 2016-07-28
MA41580A (fr) 2017-11-29
EP3247405B1 (en) 2019-07-17
UY36523A (es) 2016-08-31
AU2016209968B2 (en) 2018-11-29
AU2016209968A1 (en) 2017-07-20
EA201791668A1 (ru) 2017-11-30
CN107406490A (zh) 2017-11-28
WO2016116842A1 (en) 2016-07-28
SG11201704758XA (en) 2017-08-30
PH12017501112A1 (en) 2017-11-27
CO2017007244A2 (es) 2017-10-10
KR20170103970A (ko) 2017-09-13
IL253105A0 (en) 2017-08-31
WO2016116842A9 (en) 2016-12-08
MX2017009534A (es) 2018-04-10
AR104479A1 (es) 2017-07-26
CA2972871A1 (en) 2016-07-28
TW201632197A (zh) 2016-09-16

Similar Documents

Publication Publication Date Title
CU24266B1 (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca
EA201690282A1 (ru) Биоконъюгаты синтетических апелиновых полипептидов
CU20160013A7 (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardíaca
UY35144A (es) Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CU20170093A7 (es) Conjugados de ácidos grasos y apelina sintética con mayor vida media
CY1123307T1 (el) Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
PH12015500375A1 (en) Nep inhibitors for treating diseases characterized by atrial enlargemenet or remodeling
JP2018048157A5 (es)
PE20241305A1 (es) Analogos de amilina
ES2765281T3 (es) Coadministración de un agente unido a un péptido de interiorización con un agente antiinflamatorio
JP2015506370A5 (es)
JP2016527249A5 (es)
HRP20110086T1 (hr) Dha esteri i njihova upotreba u tretmanu i prevenciji kardiovaskularnih bolesti
EA201070315A1 (ru) Жидкая лекарственная форма конъюгата
JP2018507187A5 (es)
WO2016084935A1 (ja) Ｉｉｉ型コラーゲン産生促進剤
JP7107968B2 (ja) 血管新生を促進する薬剤ならびにその方法および使用
HRP20150265T1 (hr) Pantenil-dokosaheksanoat i njegova upotreba za lijeäśenje i sprjeäśavanje kardiovaskularnih bolesti
TN2016000029A1 (en) Bioconjugates of synthetic apelin polypeptides
MA38864A1 (fr) Polypeptides cycliques pour le traitement de l&#39;insuffisance cardiaque